Get answers to common questions about support and resources from Genentech for patients who have been prescribed ACTEMRA.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
Khanna D, Tashkin DP, Denton CP, et al. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020;201(6):650-660.
Khanna D, Tashkin DP, Denton CP, et al. Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2020;201(6):650-660.
Fischer A, Patel NM, Volkmann ER. Interstitial lung disease in systemic sclerosis: focus on early detection and intervention. Open Access Rheumatol. 2019;11:283-307.
Fischer A, Patel NM, Volkmann ER. Interstitial lung disease in systemic sclerosis: focus on early detection and intervention. Open Access Rheumatol. 2019;11:283-307.
Roofeh D, Distler O, Allanore Y, Denton CP, Khanna D. Treatment of systemic sclerosis–associated interstitial lung disease: lessons from clinical trials. J Scleroderma Relat Disord. 2020;5(2S):61-71.
Roofeh D, Distler O, Allanore Y, Denton CP, Khanna D. Treatment of systemic sclerosis–associated interstitial lung disease: lessons from clinical trials. J Scleroderma Relat Disord. 2020;5(2S):61-71.
Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019;20(1):13.
Cottin V, Brown KK. Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respir Res. 2019;20(1):13.
Khanna D, Jin C, Furst E, Goldin J, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963-974.
Khanna D, Jin C, Furst E, Goldin J, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963-974.
Data on file. Clinical Studies. Genentech, Inc. 2020.
Data on file. Clinical Studies. Genentech, Inc. 2020.
Data on file. Summary of Clinical Safety. Overview of Adverse Events for All Patients and Patients with SSc-ILD Up to Week 48 (Table 24). Genentech, Inc.
Data on file. Summary of Clinical Safety. Overview of Adverse Events for All Patients and Patients with SSc-ILD Up to Week 48 (Table 24). Genentech, Inc.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.